Deferoxamine mesylate

Research use only, not for human use.

An iron chelator that binds iron and aluminium; increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress.

An iron chelator that binds iron and aluminium; increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress.Other Indication Approved(In Vitro):Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells.Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels.Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs.Deferoxamine mesylate (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs.Deferoxamine mesylate (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells.(In Vivo):Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice.Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo.

Western Blot AnalysisCell Line:MEFs cellsConcentration:1 mMIncubation Time:16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)Result:Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions.Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.Western Blot AnalysisCell Line:HepG2 cells Concentration:100 μM Incubation Time:24 hResult:Showed a twofold increase of InsR mRNA levels in cells.Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.Cell Proliferation Assay Cell Line:TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))Concentration:5, 10, 25, 50, 100 μMIncubation Time:7 days (TAMSCs); 9 days (BMMSCs)Result:Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 μM dose.Apoptosis Analysis Cell Line:TAMSCs, BMMSCs Concentration:5, 10, 25, 50, 100 μM Incubation Time:7 days Result:Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.Western Blot AnalysisCell Line:TAMSCs, BMMSCs Concentration:10 μM Incubation Time:3 days Result:Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.Cell Autophagy AssayCell Line:SH-SY5Y cells Concentration:100 μM Incubation Time:24 h Result:Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection.

Animal Model:Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model).Dosage:6.57 μg/per (10 uL of 1 mM)Administration:Drip-on; once daily for 21 days.Result:Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.Animal Model:Male Sprague-Dawley rats (180-200 g).Dosage:200 mg/kg Administration:Intraperitoneal injection; daily for 2 weeks.Result:Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.

Desferrioxamine B mesylate | DFOM

Others

Other Targets

Aluminum|Iron

Other Indications

Other Disease

138-14-7

656.7897

C26H52N6O11S

>98% (HPLC)

H2O: ≥ 33 mg/mL

CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN

Butanediamide, N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years